Surgical Implantation of Revakinagene Taroretcel-lwey

Show Description +

Charles C. Wykoff, MD, PhD, performs one of the first commercial procedures using encapsulated cell-based gene therapy Encelto (revakinagene taroretcel-lwey) for a patient with idiopathic Macular Telangiectasia Type 2 (MacTel).

Posted: 8/12/2025

Surgical Implantation of Revakinagene Taroretcel-lwey

Charles C. Wykoff, MD, PhD, performs one of the first commercial procedures using encapsulated cell-based gene therapy Encelto (revakinagene taroretcel-lwey) for a patient with idiopathic Macular Telangiectasia Type 2 (MacTel).

Posted: 8/12/2025

Please log in to leave a comment.

More in Retina

Staining Under Air

Frédéric Aissani, MD

Assessing Surgical Competency Among Retina Fellows: Perspectives from Directors and Graduates

Nikisha Kothari, MD; Jesse Sengillo, MD; and Nicholas Farber, MD

Anti-VEGF for Proliferative Sickle Cell Retinopathy

Maria Berrocal, MD and Jennifer Lim, MD

Spotlight on UNITY® VCS: UNITY for All

Sarwar Zahid, MD, FASRS; John W. Kitchens, MD; and Matthew A. Cunningham, MD, FASRS